Team:Warwick/Human/Changes
From 2014.igem.org
(Difference between revisions)
Line 79: | Line 79: | ||
We decided to conduct a Q + A session, in which academics, students and the wider public were in attendance. Whilst lost of interesting questions were asked, we collectively became stuck when faced with the following question: | We decided to conduct a Q + A session, in which academics, students and the wider public were in attendance. Whilst lost of interesting questions were asked, we collectively became stuck when faced with the following question: | ||
- | <br> <p> What have you done to ensure your system is | + | <br> <p> What have you done to ensure your system is safe? </p> </br> |
- | + | ||
+ | <br> <p> Having reflected on this question, we realized that we failed to consider how our system would be safe - as one of the main applications of our system was to help treat Diabetes, we had to re-think and go back to the drawing board. We came up with two ideas which we feel will greatly improve the safety, but also the efficiency of our system </p> </br> | ||
+ | <br> <p> Aptazyme </p> </br> | ||
Revision as of 20:56, 17 October 2014
Project Specific Changes
As part of the project we looked to spread synthetic biology throughout the community. We approached this feat through several different avenues.
Our project came into fruition after extensive debate and discussion, the idea of introducing a mechanism by which RNA can be propagated is both conceptually and theoretically appealing. Using our replicon system to target production of a siRNA directed against a target (DPP-IV) shows just one of many applications that our system holds. Initially, it was not so straight forward when considering additional elements that we might require – for safety of the system was not on our minds. However, after due deliberation we decided to embark and ask questions and most importantly, seek answers. We started small and simple, with the obvious question on how people perceive our system? We decided to conduct a Q + A session, in which academics, students and the wider public were in attendance. Whilst lost of interesting questions were asked, we collectively became stuck when faced with the following question:
What have you done to ensure your system is safe?
Having reflected on this question, we realized that we failed to consider how our system would be safe - as one of the main applications of our system was to help treat Diabetes, we had to re-think and go back to the drawing board. We came up with two ideas which we feel will greatly improve the safety, but also the efficiency of our system
Aptazyme